Use of dihydrolipoic acid in the manufacture of a medicament for the control of diseases caused by retroviruses.

The invention relates to the use of dihydrolipoic acid for producing a drug for controlling diseases caused by retroviruses. The dosage unit for solid or semisolid preparations contains from 601 mg to 6 g, in particular from 610 mg to 2 g, preferably from 650 mg to 1 g, of dihydrolipoic acid or a pharmaceutically acceptable salt thereof, or else it contains, when it is a matter of solution, suspension or emulsion preparations, from 182 mg to 1137 mg, preferably from 200 mg to 1 000 mg, in particular from 300 mg to 500 mg, of dihydrolipoic acid, or of a pharmaceutically acceptable salt thereof, per ml.